Holen Sie sich die Stockscreener-App
78.03
0.88%
0.76
Bridgebio Pharma Inc Aktie (BBIO) Neueste Nachrichten
Understanding Momentum Shifts in (BBIO) - Stock Traders Daily
BridgeBio Pharma, Inc. $BBIO Shares Acquired by Federated Hermes Inc. - MarketBeat
Movement Recap: Is BridgeBio Pharma Inc stock a value trapJuly 2025 Spike Watch & Comprehensive Market Scan Insights - baoquankhu1.vn
Assessing BridgeBio Pharma (BBIO) Valuation After Recent Share Price Volatility - Yahoo Finance
Barclays Initiates Coverage of BridgeBio Pharma (BBIO) with Overweight Recommendation - Nasdaq
Will BridgeBio Pharma Inc. benefit from government policyGold Moves & Free Fast Gain Swing Trade Alerts - mfd.ru
BBIO Sees New Analyst Initiation with 'Overweight' Rating by Bar - GuruFocus
Barclays Initiates Coverage on BridgeBio Pharma With Overweight Rating, $157 Price Target - marketscreener.com
BridgeBio Pharma stock initiated with Overweight rating by Barclays - Investing.com Canada
Barclays Begins Coverage on BridgeBio Pharma (NASDAQ:BBIO) - MarketBeat
CORRECTING and REPLACING -- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
CORRECTING and REPLACING -- BridgeBio Pharma Reports - GlobeNewswire
Biotech BridgeBio hands new recruits 31,428 stock units - Stock Titan
12 new BridgeBio hires receive stock grants vesting over time - Stock Titan
United StatesGoodwin Advises BridgeBio In $632.5 Million Convertible Senior Notes Offering Due 2033 - Mondaq
EFG Asset Management North America Corp. Increases Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma, Inc. (BBIO) Stock Analysis: Exploring a 15% Potential Upside with Robust Revenue Growth - DirectorsTalk Interviews
Quarterly Risk: What is the Moat Score of BridgeBio Pharma IncDip Buying & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Wells Fargo Remains a Buy on BridgeBio Pharma (BBIO) - Finviz
Earnings Recap: Should value investors consider BridgeBio Pharma Inc2025 Major Catalysts & Reliable Price Action Trade Plans - baoquankhu1.vn
Wells Fargo remains a buy on BridgeBio Pharma (BBIO) - MSN
Emerald Mutual Fund Advisers Trust Lowers Stock Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma stock hits all-time high at 79.88 USD By Investing.com - Investing.com Nigeria
BridgeBio Pharma (NASDAQ:BBIO) Reaches New 52-Week HighStill a Buy? - MarketBeat
BridgeBio Pharma stock hits all-time high at 79.88 USD - Investing.com
BridgeBio Pharma, Inc. $BBIO Shares Sold by Emerald Advisers LLC - MarketBeat
How BridgeBio’s (BBIO) Convertible Notes and Attruby Uptake Have Changed Its Investment Story - simplywall.st
BridgeBio Pharma Issues New Convertible Notes and Repurchases Stock - TipRanks
Bridgebio Pharma Inc Issues $632.5 Million Convertible Senior Notes Due 2033 - TradingView
Avoiding Lag: Real-Time Signals in (BBIO) Movement - Stock Traders Daily
Wells Fargo Raises Price Target on BBIO, Maintains Overweight Ra - GuruFocus
Wells Fargo & Company Raises BridgeBio Pharma (NASDAQ:BBIO) Price Target to $88.00 - MarketBeat
Analysts Remain Positive on BridgeBio Pharma, Inc. (BBIO) After Strong 2025 Results - Finviz
Analysts remain positive on BridgeBio Pharma, Inc. (BBIO) after strong 2025 results - MSN
Mizuho Markets Americas LLC Has $7.29 Million Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio prices $550 million convertible notes at 0.75% interest rate By Investing.com - Investing.com Nigeria
Latham & Watkins Advises on BridgeBio Pharma’s US$550 Million Convertible Senior Notes Offering - Latham & Watkins LLP
BridgeBio Pharma (BBIO) stock edges up after $550 million convertible notes pricing — what investors watch next - TechStock²
BridgeBio Pharma (NASDAQ:BBIO) Sees Large Volume IncreaseStill a Buy? - MarketBeat
Lobbying Update: $60,000 of BRIDGEBIO PHARMA lobbying was just disclosed - Quiver Quantitative
BridgeBio Pharma Prices $550M Convertible Notes Offering with $538.4M Net Proceeds Expected - Intellectia AI
BridgeBio Pharma prices $550M convertible bond offering - MSN
BridgeBio Pharma Prices $550 Million Convertible Notes Offering - Intellectia AI
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
BridgeBio Pharma prices $550 million convertible notes offering By Investing.com - Investing.com Canada
BridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027 - The Manila Times
BridgeBio Pharma Prices $550 Mln Of 0.75% Convertible Senior Notes Due 2033 - Nasdaq
BridgeBio prices $550 million convertible notes at 0.75% interest rate - Investing.com
BridgeBio Pharma, Inc. Announces Pricing of $550 Million Convertible Senior Notes to Enhance Capital Structure and Extend Debt Maturity - Quiver Quantitative
BridgeBio Prices Offering of $550 Million Convertible - GlobeNewswire
BridgeBio Pharma (NASDAQ:BBIO) Shares Gap DownHere's What Happened - MarketBeat
BridgeBio’s US$550 Million Notes Offering and ATTR-CM Push Could Be A Game Changer For BBIO - Yahoo Finance
Assessing BridgeBio Pharma (BBIO) Valuation After Attruby Uptake And Pipeline Progress - Yahoo Finance
BridgeBio plans $550 million convertible notes offering to refinance debt By Investing.com - Investing.com Nigeria
BridgeBio plans $550M convertible notes offering due 2033 - MSN
0.57%
2.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):